PB-103

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NamePB-103
Drug Alias NameMDT-01PB-103
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPrecision Biotech Taiwan Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou MDT Medical Technology Co LtdPrecision Biotech Taiwan Corp
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A